Leap therapeutics announces completion of enrollment for first-line patient cohort in study of dkn-01 in combination with tislelizumab for the treatment of gastric or gastroesophageal junction cancer

Cambridge, mass., april 1, 2021 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the completion of enrollment for the first-line patient cohort in the distinguish study, a clinical trial evaluating leap's anti-dickkopf-1 (dkk1) antibody, dkn-01, in combination with tislelizumab, beigene ltd.
LPTX Ratings Summary
LPTX Quant Ranking